{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(2)"],"submitter":["Hurwitz JT"],"funding":["Roche Tissue Diagnostics"],"pubmed_abstract":["<h4>Introduction</h4>Accurate PD-L1 testing for non-small cell lung cancer (NSCLC) maximizes the benefits of immune checkpoint inhibitor (ICI) drugs like pembrolizumab. False negative test results deny ICI treatments to eligible patients, worsening clinical and economic outcomes, while false positives increase costs by using ICI treatments without their benefits. This study evaluates the cost-effectiveness of PD-L1 testing with an in vitro diagnostic (IVD) compared to a laboratory-developed test (LDT) for allocating patients with NSCLC to treatment with either pembrolizumab or chemotherapy using the German healthcare system as a model.<h4>Methods</h4>We developed a decision analytical model to evaluate the cost-effectiveness of PD-L1 testing with a regulatory body approved IVD compared to "],"journal":["Oncology and therapy"],"pagination":["391-409"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9681966"],"repository":["biostudies-literature"],"pubmed_title":["Cost-Effectiveness of PD-L1 Testing in Non-Small Cell Lung Cancer (NSCLC) Using In Vitro Diagnostic (IVD) Versus Laboratory-Developed Test (LDT)."],"pmcid":["PMC9681966"],"pubmed_authors":["Vaffis S","Nielsen S","Grizzle AJ","Dodson A","Hurwitz JT","Parry S"],"additional_accession":[]},"is_claimable":false,"name":"Cost-Effectiveness of PD-L1 Testing in Non-Small Cell Lung Cancer (NSCLC) Using In Vitro Diagnostic (IVD) Versus Laboratory-Developed Test (LDT).","description":"<h4>Introduction</h4>Accurate PD-L1 testing for non-small cell lung cancer (NSCLC) maximizes the benefits of immune checkpoint inhibitor (ICI) drugs like pembrolizumab. False negative test results deny ICI treatments to eligible patients, worsening clinical and economic outcomes, while false positives increase costs by using ICI treatments without their benefits. This study evaluates the cost-effectiveness of PD-L1 testing with an in vitro diagnostic (IVD) compared to a laboratory-developed test (LDT) for allocating patients with NSCLC to treatment with either pembrolizumab or chemotherapy using the German healthcare system as a model.<h4>Methods</h4>We developed a decision analytical model to evaluate the cost-effectiveness of PD-L1 testing with a regulatory body approved IVD compared to ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-04-18T17:07:25.362Z","creation":"2025-04-07T04:40:23.683Z"},"accession":"S-EPMC9681966","cross_references":{"pubmed":["35556235"],"doi":["10.1007/s40487-022-00197-1"]}}